Radha Andukuri, MD
Endocrinology, Diabetes & Metabolism · Omaha, NENPI 1992921779
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 169 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,183 and has fallen 57.2% since, to $507 in 2025.
Across 169 payments — averaging $21.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aimmune Therapeutics, Inc.$740
- Amgen$308
- Novo Nordisk$302
- Lilly USA, LLC$279
- Medtronic$236
- Abbott$213
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,655100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aimmune Therapeutics, Inc. | 1 | $740 |
| Amgen(2 entities) | 19 | $308 |
| Novo Nordisk | 24 | $302 |
| Lilly USA, LLC | 16 | $279 |
| Medtronic(2 entities) | 11 | $236 |
| Abbott | 13 | $213 |
| AbbVie | 11 | $176 |
| Nestle Healthcare Nutrition Inc. | 1 | $150 |
| Ascensia Diabetes Care US Inc. | 7 | $127 |
| Bayer | 8 | $126 |
| Antares Pharma, Inc. | 5 | $101 |
| Sanofi-aventis U.S. LLC | 6 | $99 |
| AstraZeneca | 6 | $87 |
| Insulet Corporation | 5 | $86 |
| Radius Health, Inc. | 5 | $77 |
| Senseonics, Incorporated | 2 | $58 |
| Xeris Pharmaceuticals, Inc. | 3 | $57 |
| Boehringer Ingelheim | 3 | $44 |
| Amneal Pharmaceuticals LLC | 3 | $43 |
| Johnson & Johnson | 2 | $38 |
| Mannkind Corporation | 2 | $35 |
| Dexcom, Inc. | 2 | $33 |
| Recordati_rare_diseases_inc. | 1 | $31 |
| Tandem Diabetes Care, Inc. | 2 | $26 |
| Amryt Pharma Holdings Ltd | 1 | $22 |
| Halozyme Inc | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Averitas Pharma Inc. | 1 | $19 |
| Valeritas, Inc. | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Cequr Corporation | 1 | $17 |
| Ascendis Pharma Endocrinology Inc | 1 | $16 |
| Sequel Med Tech, LLC | 1 | $15 |
| IBSA Pharma Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,668 in reported general payments places this provider in the 65th percentile of 43 endocrinology, diabetes & metabolism providers in Nebraska.
See all endocrinology, diabetes & metabolism providers in Nebraska →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 218 | $233,706 |
| TrulicityDulaglutide | 189 | $201,369 |
| MounjaroTirzepatide | 166 | $188,678 |
| Tresiba Flextouch U-200Insulin Degludec | 119 | $133,660 |
| JardianceEmpagliflozin | 145 | $117,084 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 40 | $95,595 |
| Tresiba Flextouch U-100Insulin Degludec | 113 | $61,759 |
| ForteoTeriparatide | 14 | $60,848 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $45,281 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 62 | $41,913 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 36 | $40,216 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 45 | $32,701 |
| JanuviaSitagliptin Phosphate | 40 | $29,987 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 175 | $23,896 |
| Humalog Kwikpen U-100Insulin Lispro | 79 | $22,994 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Forteo, Humalog, Insulin Lispro | $279 | $458,287406 claims |
| Novo NordiskOzempic, Novolog | $302 | $237,313231 claims |
| Boehringer IngelheimJardiance | $44 | $117,084145 claims |
| AstraZenecaFarxiga | $87 | $15,05820 claims |
| AbbVieSynthroid | $176 | $8,53280 claims |
| Johnson & JohnsonInvokana | $38 | $7,96014 claims |
| Sanofi-aventis U.S. LLCLantus | $99 | $4,44326 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $43 | $2,953327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 43 endocrinology, diabetes & metabolism providers in Nebraska.
Other endocrinology, diabetes & metabolism in Omaha
- Marium IlahiOmaha$170K
- Cyrus DesouzaOmaha$86K
- Timothy WahlOmaha$41K
- Leslie EilandOmaha$17K
- Anupam KotwalOmaha$17K
- John GallagherOmaha$15K
- Andjela DrincicOmaha$14K
- Laura Graeff-ArmasOmaha$11K
- Claire BakerOmaha$6K
- Alain TaylonOmaha$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.